{
    "organizations": [],
    "uuid": "64fe4d60adff4e9e8ef16666538533f12150074f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-amneal-signs-licensing-and-supply/brief-amneal-signs-licensing-and-supply-agreement-for-mabxiences-biosimilar-to-roches-avastin-idUSFWN1SU0JE",
    "ord_in_thread": 0,
    "title": "BRIEF-Amneal Signs Licensing And Supply Agreement For mAbxience's Biosimilar To Roche's Avastin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - Amneal Pharmaceuticals Inc:\n* MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES\n* MABXIENCE - CO WILL LEAD PRODUCT, CLINICAL DEVELOPMENT AND SUBSEQUENT MANUFACTURE OF BEVACIZUMAB BIOSIMILAR\n* MABXIENCE - UNDER AGREEMENT, AMNEAL WILL GUIDE PRODUCT THROUGH REGULATORY APPROVAL, HAVE EXCLUSIVE COMMERCIALISATION RIGHTS IN U.S. Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-23T19:37:00.000+03:00",
    "crawled": "2018-05-24T20:34:21.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "amneal",
        "pharmaceutical",
        "inc",
        "mabxience",
        "amneal",
        "enter",
        "agreement",
        "bevacizumab",
        "biosimilar",
        "united",
        "state",
        "mabxience",
        "co",
        "lead",
        "product",
        "clinical",
        "development",
        "subsequent",
        "manufacture",
        "bevacizumab",
        "biosimilar",
        "mabxience",
        "agreement",
        "amneal",
        "guide",
        "product",
        "regulatory",
        "approval",
        "exclusive",
        "commercialisation",
        "right",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}